<DOC>
	<DOC>NCT00162175</DOC>
	<brief_summary>A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone.</brief_summary>
	<brief_title>PPAR-COMBO With Sulfonylurea</brief_title>
	<detailed_description />
	<criteria>Type 2 Diabetes, HbA1c &gt; 7.0% and &lt; 10.0%, mean serum triglyceride &lt; 600 mg/dL, body mass index &lt; 41 kg/m2, fasting cpeptide . 1.5 ng/mL. History of MI (myocardial infarction), coronary angioplasty or bypass graft(s), valvular disease or repair, unstable angina pectoris, transient ischemic attack (TIA), cerebrovascular attack, or cerebrovascular accident (CVA) within 6 months, congestive heart failure (NYHA Class III and IV, uncontrolled hypertension, history or renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>